Search research articles
Contact Us
Filters
Showing results (121-130 of 146) with videos related to
Page
of 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
ACS Physical Chemistry Au
|
March 1, 2023
Probing the Physicochemical Behavior of Variously Doped Li<sub>4</sub>Ti<sub>5</sub>O<sub>12</sub> Nanoflowers
Kenna L Salvatore, Mallory N Vila, Genesis Renderos, et al.
Journal of Transcultural Nursing : Official Journal of the Transcultural Nursing Society
|
August 4, 2018
Health Care Provider's Role in Obesity Prevention and Healthy Development of Young American Indian Children
Chelsea L Kracht, Susan B Sisson, Kelly Kerr, et al.
Preventive Medicine Reports
|
July 14, 2018
Using community-based participatory research to develop healthy retail strategies in Native American-owned convenience stores: The THRIVE study
Valarie Blue Bird Jernigan, Mary Williams, Marianna Wetherill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C Cremolini, F Loupakis, C Antoniotti, et al.
ESMO Open
|
February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
C Antoniotti, M Carullo, D Rossini, et al.
ESMO Open
|
April 13, 2024
Treatment of patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
M M Germani, G Vetere, F Santamaria, et al.
The Pharmacogenomics Journal
|
February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients
F Loupakis, C Antoniotti, C Cremolini, et al.
British Journal of Cancer
|
July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 146) with videos related to
Sort By:
Page
of 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
ACS Physical Chemistry Au
|
March 1, 2023
Probing the Physicochemical Behavior of Variously Doped Li<sub>4</sub>Ti<sub>5</sub>O<sub>12</sub> Nanoflowers
Kenna L Salvatore, Mallory N Vila, Genesis Renderos, et al.
Journal of Transcultural Nursing : Official Journal of the Transcultural Nursing Society
|
August 4, 2018
Health Care Provider's Role in Obesity Prevention and Healthy Development of Young American Indian Children
Chelsea L Kracht, Susan B Sisson, Kelly Kerr, et al.
Preventive Medicine Reports
|
July 14, 2018
Using community-based participatory research to develop healthy retail strategies in Native American-owned convenience stores: The THRIVE study
Valarie Blue Bird Jernigan, Mary Williams, Marianna Wetherill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C Cremolini, F Loupakis, C Antoniotti, et al.
ESMO Open
|
February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
C Antoniotti, M Carullo, D Rossini, et al.
ESMO Open
|
April 13, 2024
Treatment of patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
M M Germani, G Vetere, F Santamaria, et al.
The Pharmacogenomics Journal
|
February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients
F Loupakis, C Antoniotti, C Cremolini, et al.
British Journal of Cancer
|
July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, et al.
Page
of 15